Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Antibodies to combat viral infections: development strategies and progress
Giuseppe Pantaleo, Bruno E. Correia, Craig Fenwick, et al.
Nature Reviews Drug Discovery (2022) Vol. 21, Iss. 9, pp. 676-696
Open Access | Times Cited: 154

Showing 1-25 of 154 citing articles:

Therapeutic strategies for COVID-19: progress and lessons learned
Guangdi Li, Rolf Hilgenfeld, Richard J. Whitley, et al.
Nature Reviews Drug Discovery (2023) Vol. 22, Iss. 6, pp. 449-475
Open Access | Times Cited: 411
Therapeutic advances in COVID-19
Naoka Murakami, Robert Hayden, Thomas Hills, et al.
Nature Reviews Nephrology (2022) Vol. 19, Iss. 1, pp. 38-52
Open Access | Times Cited: 133
Biologics, theranostics, and personalized medicine in drug delivery systems
Matteo Puccetti, Marilena Pariano, Aurélie Schoubben, et al.
Pharmacological Research (2024) Vol. 201, pp. 107086-107086
Open Access | Times Cited: 67
Aggregation-Induced Emission Luminogen: Role in Biopsy for Precision Medicine
Yanhong Duo, Lei Han, Yaoqiang Yang, et al.
Chemical Reviews (2024) Vol. 124, Iss. 20, pp. 11242-11347
Open Access | Times Cited: 18
Zika virus vaccines and monoclonal antibodies: a priority agenda for research and development
Julie Ostrowsky, Leah C. Katzelnick, Nigel Bourne, et al.
The Lancet Infectious Diseases (2025)
Closed Access | Times Cited: 2
Recent Advances in the Development of Monoclonal Antibodies and Next-Generation Antibodies
Rohit Singh, Pankaj Chandley, Soma Rohatgi
ImmunoHorizons (2023) Vol. 7, Iss. 12, pp. 886-897
Open Access | Times Cited: 30
Therapeutic Antibodies in Medicine
Prerna Sharma, Rahul V. Joshi, Robert C. Pritchard, et al.
Molecules (2023) Vol. 28, Iss. 18, pp. 6438-6438
Open Access | Times Cited: 29
Human IgG Fc-engineering for enhanced plasma half-life, mucosal distribution and killing of cancer cells and bacteria
Stian Foss, Siri Aastedatter Sakya, Leire Aguinagalde, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 13
Next-generation vaccines for influenza B virus: advancements and challenges
M. Ashraf, Muhammad Asif Raza, Azka Imran, et al.
Archives of Virology (2025) Vol. 170, Iss. 2
Closed Access | Times Cited: 1
Amino Acids Frequency and Interaction Trends: Comprehensive Analysis of Experimentally Validated Viral Antigen–Antibody Complexes
Roylan Pais, Anil Kumar Nagraj, Riya Patel, et al.
Molecular Biotechnology (2025)
Closed Access | Times Cited: 1
SARS-CoV-2 Variants: Genetic Insights, Epidemiological Tracking, and Implications for Vaccine Strategies
Fatimah S. Alhamlan, Ahmed A. Al‐Qahtani
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 3, pp. 1263-1263
Open Access | Times Cited: 1
Intranasal administration of a panreactive influenza antibody reveals Fc-independent mode of protection
Anna L. Beukenhorst, Keira L. Rice, Jacopo Frallicciardi, et al.
Scientific Reports (2025) Vol. 15, Iss. 1
Open Access | Times Cited: 1
Expert consensus on the diagnosis, treatment, and prevention of respiratory syncytial virus infections in children
Xian-Li Zhang, Xi Zhang, Hua Wang, et al.
World Journal of Pediatrics (2023) Vol. 20, Iss. 1, pp. 11-25
Open Access | Times Cited: 20
Fc-mediated functions of nirsevimab complement direct respiratory syncytial virus neutralization but are not required for optimal prophylactic protection
Tyler Brady, Corinne Cayatte, Tiffany Barnes, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 18
Monoclonal antibody applications in travel medicine
Hanna K. de Jong, Martin P. Grobusch
Tropical Diseases Travel Medicine and Vaccines (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 6
Sequence-specific targeting of intrinsically disordered protein regions
Kejia Wu, Hanlun Jiang, Derrick R. Hicks, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 6
The Burden of Antimicrobial Resistance in Zambia, a Sub-Saharan African Country: A One Health Review of the Current Situation, Risk Factors, and Solutions
Steward Mudenda, Webrod Mufwambi, Shafiq Mohamed
Pharmacology & Pharmacy (2024) Vol. 15, Iss. 12, pp. 403-465
Open Access | Times Cited: 6
A broad-spectrum macrocyclic peptide inhibitor of the SARS-CoV-2 spike protein
Vito Thijssen, Daniel L. Hurdiss, Oliver J. Debski-Antoniak, et al.
Proceedings of the National Academy of Sciences (2023) Vol. 120, Iss. 26
Open Access | Times Cited: 15
A novel nanobody broadly neutralizes SARS‐CoV‐2 via induction of spike trimer dimers conformation
Yang Yang, Junfang Zhang, Shengnan Zhang, et al.
Exploration (2023) Vol. 4, Iss. 3
Open Access | Times Cited: 15
Review of therapeutic mechanisms and applications based on SARS-CoV-2 neutralizing antibodies
Mingtao Liu, Hui Gan, Zhiman Liang, et al.
Frontiers in Microbiology (2023) Vol. 14
Open Access | Times Cited: 13
Monoclonal antibodies for prophylaxis and therapy of respiratory syncytial virus, SARS-CoV-2, human immunodeficiency virus, rabies and bacterial infections: an update from the World Association of Infectious Diseases and Immunological Disorders and the Italian Society of Antinfective Therapy
Susanna Esposito, Gayatri Amirthalingam, Matteo Bassetti, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 13
Clinical research on RSV prevention in children and pregnant women: progress and perspectives
Xuejia Gong, Erdan Luo, Fan Li, et al.
Frontiers in Immunology (2024) Vol. 14
Open Access | Times Cited: 5
Overcoming antibody-resistant SARS-CoV-2 variants with bispecific antibodies constructed using non-neutralizing antibodies
Tetsuya Inoue, Yuichiro Yamamoto, Kaoru Sato, et al.
iScience (2024) Vol. 27, Iss. 4, pp. 109363-109363
Open Access | Times Cited: 5
Modeling the emergence of viral resistance for SARS-CoV-2 during treatment with an anti-spike monoclonal antibody
Tin Phan, Carolin Zitzmann, Kara W. Chew, et al.
PLoS Pathogens (2024) Vol. 20, Iss. 4, pp. e1011680-e1011680
Open Access | Times Cited: 5
From Detection to Protection: Antibodies and Their Crucial Role in Diagnosing and Combatting SARS-CoV-2
Anoop Kumar, Prajna Tripathi, Prashant Kumar, et al.
Vaccines (2024) Vol. 12, Iss. 5, pp. 459-459
Open Access | Times Cited: 5
Page 1 - Next Page

Scroll to top